Esperion Therapeutis.Inc. diskutieren
Esperion Therapeutis.Inc.
WKN: A1W1SJ / Symbol: ESPR / Name: Esperion / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
1,94 €
2,00 %
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
Ratings data for ESPR provided by MarketBeat
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its price target raised by analysts at Needham & Company LLC from $12.00 to $16.00. They now have a "buy" rating on the stock.
Ratings data for ESPR provided by MarketBeat
Esperion Therapeutics, Inc. (NASDAQ: ESPR) was downgraded by analysts at Northland Securities from a "market perform" rating to an "underperform" rating.
Ratings data for ESPR provided by MarketBeat
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.
Ratings data for ESPR provided by MarketBeat
Esperion Therapeutics, Inc. (NASDAQ: ESPR) was upgraded by analysts at Bank of America Co. from an "underperform" rating to a "buy" rating. They now have a $4.00 price target on the stock, up previously from $1.25.
Ratings data for ESPR provided by MarketBeat
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its price target lowered by analysts at Needham & Company LLC from $10.00 to $9.00. They now have a "buy" rating on the stock.
Ratings data for ESPR provided by MarketBeat
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
Ratings data for ESPR provided by MarketBeat
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $9.00 price target on the stock.
Ratings data for ESPR provided by MarketBeat
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its price target lowered by analysts at Needham & Company LLC from $9.00 to $8.00. They now have a "buy" rating on the stock.
Ratings data for ESPR provided by MarketBeat
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
Ratings data for ESPR provided by MarketBeat
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
Ratings data for ESPR provided by MarketBeat
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its price target lowered by analysts at HC Wainwright from $22.00 to $16.00. They now have a "buy" rating on the stock.
Ratings data for ESPR provided by MarketBeat
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
Ratings data for ESPR provided by MarketBeat
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Ratings data for ESPR provided by MarketBeat
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
Ratings data for ESPR provided by MarketBeat
Neueste Beiträge
StockNews_com in Farmer Brothers Co. diskutieren